David G. Menter, Ph.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
About Dr. David G. Menter
startfragment
startfragment
My administrative expertise is well suited to overseeing the daily operation of the Administrative Core A. I am currently an Assistant Professor with a primary appointment in the Department of Cancer Biology at MDACC. I am also Director of Dr. DuBois’ Laboratory. I trained with Dr. Kenneth V. Honn and Dr. Lawrence Marnett in the study of prostaglandins in the molecular and cellular biology of cancer. My experience with prostaglandins and other bioactive lipids extends back to a published chapter in “Prostaglandins and Cancer: The First International Conference” in 1981. After coming to the University of Texas M D Anderson Cancer Center, I worked as an Assistant Professor and helped Dr. Scott M. Lippman to establish the Department of Clinical Cancer Prevention in the Division of Cancer Prevention. I also helped to establish the Lung Cancer Biomarkers Core Program in the Department of Thoracic Head and Neck Medical Oncology at the Institution under the supervision of Drs. Scott M. Lippman and Waun Ki Hong. I am currently serving as the Director of Dr. Raymond N. DuBois’ Laboratory and will act as the Core A Co-Director. I have extensive experience in the study of prostaglandins and bioactive lipids in cancer biology.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
I am interested in the molecular and cellular biology of gastrointestinal tumors. These studies involve four primary areas of research: 1) to understand microenvironmental and age related effects of the colon stromal on CRC; 2) to examine the role of the stromal cell eicosanoid pathway and inflammatory pathway effects on CRC; 3) to examine the role of mesenchymal and epithelial stem cells in the development of CRC and 4) to develop mechanism based approaches of applying nanotechnology to cancer prevention. These studies involve isolating and characterizing cells from colon tumors as well as colon liver metastases. These cells will be used in co-culture experiments with colon tumor cells to examine the their ability to inhibit or promote the growth of tumor cells in vitro or in vivo. Further molecular and eicosanoid profiling will be performed co-cultured cells to dissect out the critical changes that occur when these cells interact during tumor formation. In the future, As a part of the age related effects of stromal cells on CRC, in the process of isolating normal colon and pancreatic mesenchymal and epithelial cells from various age wt or APCmin mice. These mesenchymal cells will be used in co-culture experiments with colon tumor cells to examine the effect of age or inflammatory bioactive lipids on the ability of mesenchymal cells to inhibit or promote the growth of tumor cells in vitro or in vivo.
Education & Training
Degree-Granting Education
| 1986 | Wayne State University, Detroit, Michigan, US, Cell Biology, Ph.D |
| 1976 | Wayne State University, Detroit, Michigan, US, Biology, BS |
Postgraduate Training
| 1986-1992 | Research Fellowship, Cell Biology, The University of Texas, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2014
Assistant Professor, Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, 2006 - 2007
Assistant Professor, Clinical Cancer Prevention - Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1996 - 2007
Research Associate, Department of Tumor Biology, University of Texas M. D. Anderson Cancer Center, Houston, TX, 1992 - 1996
Postdoctoral Fellow, Department of Tumor Biology, University of Texas M. D. Anderson Cancer Center, Houston, TX, 1986 - 1992
Graduate Research Assistant, Department of Radiation Oncology, Wayne State University, Detroit, MI, 1982 - 1986
Graduate Research Assistant, Department of Biochemistry, Wayne State University, Detroit, MI, 1981 - 1982
Graduate Research Assistant, Department of Pharmacology, Wayne State University, Detroit, MI, 1978 - 1979
Graduate Research Assistant, Department of Biological Sciences, Wayne State University, Detroit, MI, 1976 - 1977
Administrative Appointments/Responsibilities
Administrative Director, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2014
Clinical Cancer Prevention Management Team, Clinical Cancer Prevention - Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1996 - 1998
Tumor Biology Computer Network Administrator, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1988 - 1996
Other Professional Positions
Full Member, NIEHS Center for Research on Environmental Disease, Smithville, TX, 2003 - 2006
Extramural Institutional Committee Activities
Chair, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present
Member, Export Controls Faculty Advisory Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present
Member, Vet Med North Campus Section Head Search Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Committee Member, Animal Research Infrastructure Strategic Planning Committee, The University of Texas MD Anderson Cancer Center, 2008 - Present
Poster Judge, Colorectal Cancer: Celebrating a Career in Prevention, The University of Texas MD Anderson Cancer Center, 2007
Member, Thoracic/Head & Neck Medical Oncology Research Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2007
Member, User Committee for the Analytical Core of the UTMDACC Cancer Center Support Grant, The University of Texas MD Anderson Cancer Center, 2005 - Present
Member, GSBS Scholarship Award Committee, T.C. Hsu Endowed Memorial Scholarship, The University of Texas MD Anderson Cancer Center, 2004
Judge, University of Texas M. D. Anderson Cancer Center Trainee Recognition Day, The University of Texas MD Anderson Cancer Center, 2004
Poster Judge, Day of Prevention Science, The University of Texas MD Anderson Cancer Center, 2004
Member, Faculty Achievement Award Committee, Margaret and James A. Elkins Award in Prevention, The University of Texas MD Anderson Cancer Center, 2001
Member, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 1999 - Present
Alternate member, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1999
Member, M. D. Anderson Internet Steering Committee, The University of Texas MD Anderson Cancer Center, 1997
Member, M. D. Anderson Network Technical Advisory Council, The University of Texas MD Anderson Cancer Center, 1994 - 1997
Representative, Anderson Associates, The University of Texas MD Anderson Cancer Center, 1989 - 1991
Honors & Awards
| 2002 | HSC Honors Convocation Recipient, University of Texas Health Science Center |
| 1998 | Flemming and Davenport Award, Texas Medical Center |
| 1997 | Shannon Award, National Cancer Institute |
| 1997 | Postdoctoral Support Award, Meadows Foundation |
| 1987 | Histopathobiology of Neoplasia Workshop, National Cancer Institute |
| 1986 | National Cancer Institute Postdoctoral Fellow in Human Genetics, National Cancer Institute |
| 1984 | Outstanding Researcher Award, Sigma Xi: The Scientific Research Society |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2014. Novel Stem Cell Imaging and Targeting of Tumors: Metabolism in Cancer. Conference. Department of Cancer Systems Imaging, US.
- 1997. Computer Analysis of Tumor Cell Adhesion and Stabilization: role of integrins. Conference. FASEB Annual Meeting. Washington, DC, US.
International Presentations
- 1996. Brain Metastatic Melanoma Interactions with Cultured-Brain Astrocytes. Conference. American Association for Cancer Research. Washington, US.
- 1995. p75 Neurotrophin Receptor-mediated Trophism as a Malignant Melanoma Cell Survial Mechanism. Conference. American Association of Cancer Research. Toronto, CA.
- 1994. Human Melanoma Adhesion Stabilizaiton to Extracellular Matrix Components under Fluid Shear Correlates with Integrin Expression and Metastatic Properties. Conference. American Association for Cancer Research. San Francisco, US.
- 1992. Stabilization of tumor cell adhesion to fibronectin under fluid shear stress: association with transglutaminase activity in human metastatic melanoma variants. Conference. Third International Conferenceon Transglutaminase and Protein Crosslinking Reactions. Ardmore, US.
- 1990. Effects of transglutaminase inhibitors melanoma cell interactions with immobilized fibronectin. Conference. Third International Congress of the Metastasis Research Society. Bethesda, US.
Formal Peers
- 2004. Reversing the Suppression of GSK-3beta by Akt in Prostate Carcinoma Cells. Invited. Baton Rouge, LA, US.
- 1994. NGF-stimulated extracellular matrix degradation and invasion by the human melanoma: p75NTR functions independent of p140trkA and involves a purine analog sensitive kinase. Invited. Dallas, TX, US.
- 1991. Biomechanics of Cell Metastasis Session, Effects of transglutaminase inhibitors on tumor cell adhesion, spreading and detachment under defined wall shear stress. Invited. Morgantown, WV, US.
Grant & Contract Support
| Date: | 2024 - 2028 |
| Title: | Combat early-onset colorectal cancer by integrated design and validation of innovative combination immunotherapy |
| Funding Source: | V Foundation |
| Role: | Co-I |
| ID: | FP22151 |
| Date: | 2024 - 2028 |
| Title: | Using DT2216, a platelet-sparing BCL-xL degrader, to overcome resistance to KRASG12C-EGFR inhibition in colorectal cancer |
| Funding Source: | CPRIT Subcontract with UT San Antonio |
| Role: | PI |
| ID: | FP22521 |
| Date: | 2024 - 2029 |
| Title: | OPTIMAL (Overcoming Plasticity as a Targeted Intervention for MALignancy) |
| Funding Source: | Cancer Research Foundation |
| Role: | Co-I |
| ID: | FP20896 |
| Date: | 2024 - 2029 |
| Title: | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP19688 |
| Date: | 2024 - 2027 |
| Title: | Epigenetic mechanism and targeting during response to BRAF/anti-EGFR therapy in BRAF-mutant colorectal cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | FP19853 |
| Date: | 2023 - 2028 |
| Title: | University of Texas PDX Development and Trial Center |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP17665 |
| Date: | 2023 - 2028 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP17665 |
| Date: | 2023 - 2026 |
| Title: | Advanced Approaches to Understanding and Targeting BRAF Tumors |
| Funding Source: | Gastro-Intestinal Research Foundation |
| Role: | Co-PI |
| ID: | FP18308 |
| Date: | 2023 - 2025 |
| Title: | Colorectal Cancer Biology and Risk among African Americans |
| Funding Source: | Sub w University of Kansas Medical Center |
| Role: | Co-I |
| ID: | FP16908 |
| Date: | 2022 - 2027 |
| Title: | Overcoming adaptive resistance to KRAS inhibition in CRC |
| Funding Source: | National Institutes of Health – NIH (Pass Thru Sponsor) Massachusetts General Hospital) |
| Role: | Co-I |
| ID: | FP12128_Res1 | PID14238 |
| Date: | 2022 - 2027 |
| Title: | Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA262805-01A1 |
| Date: | 2022 - 2025 |
| Title: | Targeting adaptive and acquired resistance to direct KRAS inhibition |
| Funding Source: | Stand up to Cancer – Mirati Subaward with Massachusetts General Hospital |
| Role: | Scientific Manager |
| ID: | FP14745 |
| Date: | 2021 - 2024 |
| Title: | Colorectal Cancer Molecular Subtype Assay Development and Validation |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | FP11990 |
| Date: | 2021 - 2026 |
| Title: | INTERCEPT - Colorectal Cancer Research |
| Funding Source: | E.L. and Thelma Gaylord Foundation |
| Role: | Co-I |
| ID: | FP13735 | PID12923 |
| Date: | 2021 |
| Title: | INTERCEPT – Colorectal Cancer Research |
| Funding Source: | E.L. and Thelma Gaylord Foundation |
| Role: | Co-I |
| ID: | AWD00005860 |
| Date: | 2019 - 2024 |
| Title: | Defining Therapeutic implications in HER2 amplified metastatic colorectal cancer (CRC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2019 - 2024 |
| Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer: Project 3 |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00001122 – Admin Core 001 Project |
| Date: | 2018 - 2020 |
| Title: | Colorectal Cancer Molecular Subtype Assay Development and Validation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | UH2CA207101 |
| Date: | 2018 - 2023 |
| Title: | Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP439 |
| Date: | 2017 - 2023 |
| Title: | University of Texas PDX Development and Trial Center |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | FP1549 |
| Date: | 2015 - 2016 |
| Title: | Novel prostaglandin E2 pathway targeted drugs for colorectal cancer |
| Funding Source: | CRC Moon Shot |
| Role: | PI |
| Date: | 2015 - 2016 |
| Title: | CRC-Moon Shot |
| Funding Source: | CRC Moon Shot |
| Role: | Co-I |
| Date: | 2014 - 2016 |
| Title: | Administrative/Scientific Director |
| Funding Source: | Colorectal Cancer Moon Shot |
| Role: | Project Co-Leader |
| Date: | 2014 - 2016 |
| Title: | Preclinical Studies of a Novel Safer Aspirin for Colorectal Cancer Prevention |
| Funding Source: | Duncan Foundation |
| Role: | PI |
| Date: | 2014 - 2015 |
| Title: | Evaluation of the chemopreventive activity of Aspirin-PC, in vivo using APCmin models of colorectal cancer |
| Funding Source: | Colorectal Cancer Moon Shot |
| Role: | PI |
| Date: | 2010 - 2015 |
| Title: | TEXAS CENTER FOR CANCER NANOMEDICINE |
| Funding Source: | NIH/NCI |
| Role: | Project-Co-Leader |
| ID: | 1U54CA151668-01 |
| Date: | 2010 - 2013 |
| Title: | Prostaglandins and Inflammation in Colorectal Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator-MDACC |
| ID: | RP100960 |
| Date: | 2006 - 2009 |
| Title: | Understanding Prostate Cancer Indolence and Latency |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | PC050732 |
| Date: | 2005 - 2010 |
| Title: | Novel Approaches for Understanding Selenoprotein Function in Prostate Cancer |
| Funding Source: | National Cancer Institute |
| Role: | Principal Investigator-MDACC |
| ID: | 1 RO1 |
| Date: | 2005 - 2010 |
| Title: | Novel Ideas in Prostate Cancer Indolence and Latency |
| Funding Source: | National Cancer Institute |
| Role: | Principal Investigator-MDACC |
| ID: | 1 RO1 |
| Date: | 2005 - 2008 |
| Title: | Novel Imaging Studies of Stroma in Prostate Cancer |
| Funding Source: | National Cancer Institute |
| Role: | Principal Investigator-MDACC |
| ID: | 1 R33 |
| Date: | 2005 - 2010 |
| Title: | New Tactics to Detect –Kinase Regulated Androgen Receptor |
| Funding Source: | National Cancer Institute |
| Role: | Principal Investigator-MDACC |
| ID: | 1 RO1 |
| Date: | 2003 - 2005 |
| Title: | Selenoprotein Targeting in Prostate Cancer Carciongenesis |
| Funding Source: | NCI |
| Role: | PI |
| ID: | 1R21CA102145-01 |
| Date: | 2002 - 2011 |
| Title: | Nuclear Hormone Receptors and Intestinal Epithelial Biology |
| Funding Source: | NIH/NIDDK |
| Role: | Investigator |
| ID: | 5RO1 DK62112-09 |
| Date: | 1999 - 2003 |
| Title: | Probasin-Cre-ERT Conditional Gene Targeting of COX in Mouse Prostate |
| Funding Source: | American Cancer Society, National |
| Role: | PI |
| ID: | TPRN-99-240-02-CNE |
| Date: | 1998 - 1999 |
| Title: | COX-2 Conditional Gene Targeting in Bladder Carcinogenesis |
| Funding Source: | Flemming/Davenport Award |
| Role: | Principal Investigator-MDACC |
| Date: | 1998 - 2003 |
| Title: | Phase I Clinical Studies of Chemopreventive Agents |
| Funding Source: | National Cancer Institute |
| Role: | Project Leader |
| ID: | MA-CN-07-10 |
| Date: | 1997 - 2002 |
| Title: | Phase II Clinical Trials of New Chemopreventive Agents |
| Funding Source: | National Cancer Institute |
| Role: | Co-I |
| ID: | MA-CN-08-17 |
| Date: | 1997 - 1999 |
| Title: | Evaluating Cadherins and Catenins in Invasion of Non-Melanoma Skin Cancer |
| Funding Source: | Various Donor Fund for Skin Cancer Research |
| Role: | PI |
| Date: | 1997 - 1999 |
| Title: | E-Cadherin and Beta-catenin involvement during invasion of non-melanoma skin cancer |
| Funding Source: | Meadows Foundation Grant |
| Role: | PI |
| Date: | 1997 - 2001 |
| Title: | Pilot Selenium in Prostate Activities of the Southwest Oncology Group |
| Funding Source: | Southwest Oncology Group |
| Role: | Investigator |
| ID: | S/C 5 U10 CA37429, CCOP-97014 |
| Date: | 1996 - 2000 |
| Title: | Neurotrophic Mechanisms in Melanoma Metastasis |
| Funding Source: | National Cancer Institute |
| Role: | PI |
| ID: | CA71594-01 |
| Date: | 1994 - 2013 |
| Title: | Role of Eicosanoids in Intestinal Epithelial Growth and Function |
| Funding Source: | NIH/NIDDK |
| Role: | Investigator |
| ID: | 5R37-DK47297-16 |
| Title: | Link Between IGF-1 Receptor Signaling, Akt, and Androgen Receptor(AR) and Development of a Rationale for Combination Therapies in Prostate Cancer |
| Funding Source: | CAPCURE |
| Role: | Co-I |
| Title: | Quick Trials for Prostate Cancer Therapy |
| Funding Source: | National Cancer Institute |
| Role: | Co-I |
| ID: | PA-99-070 |
| Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer |
| Funding Source: | NIH |
| Role: | PI |
| Title: | T. Boone Pickens Distinguished Chair for Early Prevention of Cancer |
| Funding Source: | University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Title: | Novel Approaches in Dietary Prevention of Prostate Cancer |
| Funding Source: | Cancer Research and Prevention Foundation |
| Role: |
| Title: | Non-invasive Colonoscopy by Molecular Imaging of Mucin Targeted Hyperpolarized Silicon Nanoparticles |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | Molecular Characterization of Aspirin for Colorectal Cancer Treatment and Prevention |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | Targeting intrinsic prostaglandin production in human melanoma cells and tumors |
| Funding Source: | ACF-Pharmaceuticals |
| Role: | Co-I |
| Title: | Selenoprotein Targeting in the Chemoprevention of Prostate Carcinogenesis |
| Funding Source: | National Cancer Institute |
| Role: | |
| ID: | R25 |
| Title: | l-Selenomethionine and Oxidative Stress: Their Effects on Cell Death and Gene Regulation in Prostate Cells |
| Funding Source: | Ronald and Rita McAulay Foundation |
| Role: |
Selected Publications
Peer-Reviewed Articles
- Morris, VK, Parseghian, C, Bahrambeigi, V, Abdelfattah, N, Xiao, L, Agrawal, A, Lin, K, Raghav, KS, Wolff, RA, Dasari, NV, Huey, RW, Kee, BK, Overman, MJ, Willis, JA, Le, PH, Escano, M, Baig, YC, Pan, K, Menter, DG, Tam, AL, Foo, WC, Shen, L, Lee, HM, Gallup, T, Margain, C, Gallup, D, Rajapakshe, K, Guerrero, PA, Wang, J, Corcoran, RB, Maitra, A, Yun, K, Kopetz, S. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer. Cancer cell 43(11):2106-2118.e3, 2025. e-Pub 2025. PMID: 40882637.
- Bayraktar, R, Tang, Y, Dragomir, M, Ivan, C, Peng, X, Fabris, L, Zhang, J, Carugo, A, Aneli, S, Liu, J, Chen, MM, Srinivasan, S, Sahnoune, I, Bayraktar, E, Akdemir, KC, Chen, M, Narayanan, P, Huang, W, Ott, LF, Eterovic, AK, Villarreal, OE, Mohammad, MM, Peoples, M, Walsh, D, Hernandez, JA, Morgan, M, Shaw, KR, Davis, JS, Menter, DG, Tam, CS, Yeh, P, Dawson, SJ, Rassenti, LZ, Kipps, TJ, Kunej, T, Estrov, Z, Joosse, SA, Pagani, L, Alix-Panabières, C, Pantel, K, Ferajoli, A, Futreal, A, Wistuba, II, Radovich, M, Kopetz, S, Keating, M, Draetta, G, Mattick, JS, Liang, H, Calin, GA. The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers. Science Advances 11(8), 2025. e-Pub 2025. PMID: 39970212.
- Lin K, Chowdhury S, Zeineddine MA, Zeineddine FA, Hornstein NJ, Villarreal OE, Maru DM, Haymaker CL, Vauthey JN, Chang GJ, Bogatenkova E, Menter D, Kopetz S, Shen JP. Identification of colorectal cancer cell stemness from single-cell RNA sequencing. Mol Cancer Res 22(4), 2024. e-Pub 2023. PMID: 38156967.
- Ngo-Huang AT, Parker NH, Xiao L, Schadler KL, Petzel MQB, Prakash LR, Kim MP, Tzeng CD, Lee JE, Ikoma N, Wolff RA, Javle MM, Koay EJ, Pant SD, Folloder JP, Wang X, Cotto AM, Ju YR, Garg N, Wang H, Bruera ED, Basen-Engquist KM, Katz MHG. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. Ann Surg 278(1):22-30, 2023. e-Pub 2023. PMID: 37026453.
- Janku F, Javle MM, Sen S, Pant S, Bramwell LG, Subbiah V, Way T, Wages DS, Wheeler CA, Suzuki T, Saeki K, Subach RA, Madden T, Maier G, Johansen MJ, Cheung K, Falchook GS. A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer 129(10):1537-1546, 2023. e-Pub 2023. PMID: 36882377.
- Ayabe RI, Paez-Arango N, Estrella JS, Newhook TE, Tzeng CD, Chun YS, Lee S, Javle M, Vauthey JN, Tran Cao HS. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes?. HPB (Oxford) 25(4):472-480, 2023. e-Pub 2023. PMID: 36781357.
- Dodoo GN, De B, Lee SS, Abi Jaoude J, Vauthey JN, Tzeng CD, Tran Cao HS, Katlowitz KA, Mandel JJ, Beckham TH, Minsky BD, Smith GL, Holliday EB, Koong AC, Das P, Taniguchi CM, Javle M, Koay EJ, Ludmir EB. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist 28(4):327-332, 2023. e-Pub 2023. PMID: 36715178.
- Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. Molecular Profiling and Treatment Pattern Differences between Intrahepatic and Extrahepatic Cholangiocarcinoma. J Natl Cancer Inst. e-Pub 2023. PMID: 37040087.
- Pant S, Dragovich T, Lieu C, Jimeno A, Kundranda M, Menter D, Tchaparian E, Chen YC, Kopetz S. Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. Invest New Drugs 41(1):25-34, 2023. e-Pub 2022. PMID: 36331676.
- Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
- Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6. Cancer Res 82(18):3335-3344, 2022. e-Pub 2022. PMID: 35913398.
- Corvigno S, Johnson AM, Wong KK, Cho MS, Afshar-Kharghan V, Menter DG, Sood AK. Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. Mol Cancer Ther 21(7):1067-1075, 2022. e-Pub 2022. PMID: 35545008.
- Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilie PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Discov 12(6):1542-1559, 2022. e-Pub 2022. PMID: 35412613.
- Kanikarla Marie P, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, Woods MN, Anderson A, Capasso A, Fowlkes N, Overman MJ, Menter DG, Kopetz S. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol 12:994333, 2022. e-Pub 2022. PMID: 36212401.
- Menter D. Where is Waldo? or find the platelet. Cancer Metastasis Rev 40(3):649-655, 2021. e-Pub 2021.
- Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, Consortium NCI, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun 12(1):5086, 2021. e-Pub 2021. PMID: 34429404.
- Marie PK, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol 11:643815, 2021. e-Pub 2021.
- Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: 33745946.
- Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
- Li Y, Baggerly KA, Orouji E, Manyam G, Chen H, Lam M, Davis JS, Lee MS, Broom BM, Menter DG, Rai K, Kopetz S, Morris JS. Methylation-eQTL Analysis in Cancer Research. Methylation-eQTL Analysis in Cancer Research 37(22):btab443, 2021. e-Pub 2021. PMID: 34117863.
- Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, Consortium P, Consortium E. Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53(5):761, 2021. e-Pub 2021. PMID: 33608693.
- Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, Consortium P, Consortium E. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53(1):86-99, 2021. e-Pub 2021. PMID: 33414553.
- Morris J, Luthra R, Liu Y, Duose D, Lee W, Reddy N, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom B, Alvarez H, Mejia A, Veeranki O, Routbort M, Morris V, Overman M, Menter D, Katkhuda R, Wistuba, II, Davis J, Kopetz S, Maru D. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res 27(1):120-130, 2021. e-Pub 2021.
- Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, Los Santos MCD, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology, 2020. e-Pub 2020. PMID: 32805281.
- Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, Los Santos MCD, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology 159(6):2146-2162, 2020. e-Pub 2020.
- Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, # SK, Maru # DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res, 2020. e-Pub 2020. PMID: 33109741.
- Davis JS, Kanikarla-Marie P, Gagea M, Yu PL, Fang D, Sebastian M, Yang P, Hawk E, Dashwood R, Lichtenberger LM, Menter D, Kopetz S. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer, 2020. e-Pub 2020. PMID: 32912193.
- Davis JS, Kanikarla-Marie P, Gagea M, Yu PL, Fang D, Sebastian M, Yang P, Hawk E, Dashwood R, Lichtenberger LM, Menter D, Kopetz S. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 20(1):871, 2020. e-Pub 2020.
- McGrail DJ, Garnett J, Yin J, Dai H, H Shih DJ, Anh Lam TN, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin S. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell, 2020. e-Pub 2020. PMID: 32109374.
- McGrail DJ, Garnett J, Yin J, Dai H, H Shih DJ, Anh Lam TN, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin S. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell 37(3):371-386, 2020. e-Pub 2020.
- Batth IS, Mitra A, Rood S, Kopetz S, Menter D, Li S. CTC analysis: an update on technological progress. Transl Res, 2019. e-Pub 2019. PMID: 31348892.
- Willauer AN, Liu Y, L Pereira AA, Lam M, Morris JS, S Raghav KP, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer, 2019. e-Pub 2019. PMID: 30854646.
- Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer 120(3):340-345, 2019. e-Pub 2019. PMID: 30636774.
- Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res 25(2):641-651, 2019. e-Pub 2019. PMID: 30352910.
- Zacharias NM, Ornelas A, Lee J, Hu J, Davis J, Uddin MN, Pudakalakatti S, Menter D, Karam JA, Wood CG, Hawk E, Kopetz S, Vilar E, Bhattacharya P, Millward S. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. e-Pub 2019. PMID: 30680862.
- Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res. e-Pub 2018. PMID: 30538110.
- Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. e-Pub 2018. PMID: 30112590.
- Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. e-Pub 2018. PMID: 28607096.
- Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2018. PMID: 29180604.
- Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol 24(13):4051-4058, 2017. e-Pub 2017. PMID: 28936799.
- Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
- Katsiampoura A, Raghav K, Jiang ZQ, {bMenter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient-Derived Xenografts in Colorectal Cancer. Mol Cancer Ther 16(7):1435-1442, 2017. e-Pub 2017. PMID: 28468778.
- Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya P, Millward S. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev 36(2):289-303, 2017. e-Pub 2017. PMID: 28762014.
- Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
- Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biol 18(1):98, 2017. e-Pub 2017. PMID: 28535802.
- Whiting N, Hu J, Zacharias NM, Lokesh GL, Volk DE, Menter DG, Rupaimoole R, Previs R, Sood AK, Bhattacharya P. Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. J Med Imaging (Bellingham) 3(3):036001, 2016. e-Pub 2016. PMID: 27547777.
- Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. e-Pub 2016. PMID: 27421137.
- Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res 29(3):297-308, 2016. e-Pub 2016. PMID: 26801201.
- Fang L, Lu W, Choi HH, Yeung SC, Tung JY, Hsiao CD, Fuentes-Mattei E, Menter DG, Chen C, Wang L, Wang J, Lee MH. ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell 28(2):183-97, 2015. e-Pub 2015. PMID: 26267535.
- Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
- Whiting N, Hu J, Shah JV, Cassidy MC, Cressman E, Zacharias Millward N, Menter DG, Marcus CM, Bhattacharya PK. Real-Time MRI-Guided Catheter Tracking Using Hyperpolarized Silicon Particles. Sci Rep 5:12842, 2015. e-Pub 2015. PMID: 26239953.
- Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet?. Cancer Prev Res (Phila) 7(10):973-92, 2014. e-Pub 2014. PMID: 25060262.
- Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RA. Cellular location and expression of Na+, K+ -ATPase α subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog 53(4):253-63, 2014. e-Pub 2014. PMID: 23073998.
- Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 33(1):231-69, 2014. e-Pub 2014. PMID: 24696047.
- Charo C, Holla V, Arumugam T, Hwang R, Yang P, Dubois RN, Menter DG, Logsdon CD, Ramachandran V. Prostaglandin E2 Regulates Pancreatic Stellate Cell Activity Via the EP4 Receptor. Pancreas 42(3):467-74, 2013. e-Pub 2013. PMID: 23090667.
- Menter DG, Dubois RN. Prostaglandins in Cancer Cell Adhesion, Migration, and Invasion. Int J Cell Biol 2012:723419, 2012. e-Pub 2012. PMID: 22505934.
- Holla VR, Wu H, Shi Q, Menter DG, DuBois RN. Nuclear Orphan Receptor NR4A2 Modulates Fatty Acid Oxidation Pathways in Colorectal Cancer. J Biol Chem 286(34):30003-9, 2011. e-Pub 2011. PMID: 21757690.
- Campbell SE, Rudder B, Phillips RB, Whaley SG, Stimmel JB, Leesnitzer LM, Lightner J, Dessus-Babus S, Duffourc M, Stone WL, Menter DG, Newman RA, Yang P, Aggarwal BB, Krishnan K. alpha-Tocotrienol induces growth arrest through a novel pathway with TGFbeta2 in prostate cancer. Free Radic Biol Med 50(10):1344-54, 2011. e-Pub 2011. PMID: 21335085.
- Menter DG, Ramsauer VP, Harirforoosh S, Chakraborty K, Yang P, Hsi L, Newman RA, Krishnan K. Differential effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites. PLoS One 6(12):e28813, 2011. e-Pub 2011. PMID: 22216116.
- Kim SH, Xia D, Kim SW, Holla V, Menter DG, Dubois RN. Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res 70(10):4054-63, 2010. e-Pub 2010. PMID: 20442290.
- Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16(5):1384-90, 2010. e-Pub 2010. PMID: 20179228.
- Xia D, Holla VR, Wang D, Menter DG, DuBois RN. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res 70(2):824-31, 2010. e-Pub 2010. PMID: 20068165.
- Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa N, Newman RA. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol Cancer Ther 8(8):2319-28, 2009. e-Pub 2009. PMID: 19671733.
- Shin S, Asano T, Yao Y, Zhang R, Claret FX, Korc M, Sabapathy K, Menter DG, Abbruzzese JL, Reddy SA. Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism. Mol Cancer Res 7(5):745-54, 2009. e-Pub 2009. PMID: 19435822.
- Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 2009. e-Pub 2009. PMID: 19244175.
- Jin Q, Menter DG, Mao L, Hong WK, Lee HY. Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis 29(8):1614-22, 2008. e-Pub 2008. PMID: 18635526.
- Guitierrez-Barrera AM, Menter DG, Abbruzzese JL, Reddy SA. Establishment of three-dimensional cultures of human pancreatic duct epithelial cells. Biochem. Biophys. Res. Commun 358:698-703, 2007. e-Pub 2007.
- Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 12:2178-84, 2006. e-Pub 2006. PMID: 16609032.
- Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 25:6015-25, 2006. e-Pub 2006. PMID: 16682954.
- Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7:280-93, 2005. e-Pub 2005. PMID: 15799828.
- Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65:6189-98, 2005. e-Pub 2005. PMID: 16024620.
- Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13:1710-6, 2004. e-Pub 2004. PMID: 15533897.
- Yang P, Chan D, Felix E, Cartwright C, Menter DG, Madden T, Klein RD, Fischer SM, Newman RA. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res 45:1030-9, 2004. e-Pub 2004. PMID: 14993240.
- Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279:19191-200, 2004. e-Pub 2004. PMID: 14985354.
- Sabichi AL, Subbarayan V, Llansa N, Lippman SM, Menter DG. PPARg suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers and Prev 13:1704-9, 2004. e-Pub 2004.
- Xu X, CShappell SB, Liang Z, Song S, Menter DG, Subbarayan V, Iyengar S, Tang DG, Lippman SM. Reduced 15-S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 5:121-7, 2003. e-Pub 2003.
- Salas TR, Reddy SA, Clifford JL, Davis RJ, Kikuchi A, Lippman SM, Menter DG. Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 278:41338-46, 2003. e-Pub 2003. PMID: 12900420.
- Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 11:587-90, 2002. e-Pub 2002. PMID: 12050101.
- Menter DG, Hoque A, Motiwala N, Sahin AA, Sneige N, Lieberman R, Lippman SM. Computerized image analysis of Ki-67 in ductal breast carcinoma in situ (DCIS). Anal Quant Cytol Histol 23:218-28, 2001. e-Pub 2001. PMID: 11444192.
- Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 61:2720-6, 2001. e-Pub 2001. PMID: 11289153.
- Hoque A, Menter DG, Sahin AA, Sneige N, Lippman SM. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 10:153-4, 2001. e-Pub 2001. PMID: 11219775.
- Papadimitriou MN, McIntire LV, Menter DG. Effect of cyclooxygenase inhibitors in the adhesion of tumor cells to endothelial cells. Crit Rev Biomed Eng 28:193-4, 2000. e-Pub 2000. PMID: 10999385.
- Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9:1171-82, 2000. e-Pub 2000. PMID: 11097224.
- Clifford JL, Menter DG, Yang X, Walch E, Zou C, Clayman GL, Schaefer TS, El-Naggar AK, Lotan R, Lippman SM. Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 9:993-7, 2000. e-Pub 2000. PMID: 11008921.
- Hong W, Lotan R, Menter DD, Lippman SM, Xu X. Expression of E-cadherin is associated with Squamous Differentiation in Squamous cell carcinomas. Exp Cancer Res., Anticancer Research 20:1385-90, 2000. e-Pub 2000.
- Schaefer LK, Menter DG, Schaefer TS. Activation of stat3 and stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines. Cell Signal 12:143-51, 2000. e-Pub 2000. PMID: 10704821.
- Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 59:14-8, 1999. e-Pub 1999. PMID: 9892176.
- Papadimitriou MN, Menter DG, Konstantopoulos K, Nicolson GL, McIntire LV. Integrin alpha4beta1/VCAM-1 pathway mediates primary adhesion of RAW117 lymphoma cells to hepatic sinusoidal endothelial cells under flow. Clin Exp Metastasis 17:669-76, 1999. e-Pub 1999. PMID: 10919712.
- Yun Z, Smith TW, Menter DG, McIntire LV, Nicolson GL. Differential adhesion of metastatic RAW117 large-cell lymphoma cells under static or hydrodynamic conditions: role of integrin alpha(v) beta3. Clinical & Experimental Metastasis 15:3-11, 1997. e-Pub 1997.
- Herrmann JL, Menter DG, Beham A, von Eschenbach A, McDonnell TJ. Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. Exp Cell Res 234:442-51, 1997. e-Pub 1997. PMID: 9260915.
- Yun Z, Menter DG, Nicolson GL. Involvement of integrin alphavbeta3 in cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma. Cancer Res 56:3103-11, 1996. e-Pub 1996. PMID: 8674068.
- Smith TW, Menter DG, Nicolson GL, McIntire LV. Signaling mechanisms in stabilization of melanoma adhesion. Melanoma Research 6:351-62, 1996. e-Pub 1996.
- Smith TW, Yun Z, Menter DG, McIntire LV, Nicolson GL. Computerized analysis of tumor cell interactions with extracellular matrix proteins, peptides and endothelial cells under laminar flow. Biotechnol. Bioengineer 50:598-607, 1996. e-Pub 1996.
- Menter DG, Fitzgerald L, Patton JT, McIntire LV, Nicolson GL. Human melanoma integrins contribute to arrest and stabilization potential while flowing over extracellular matrix. Immunol Cell Biol 73:575-83, 1995. e-Pub 1995. PMID: 8713481.
- Menter DG, Herrmann JL, Marchetti D, Nicolson GL. Involvement of neurotrophins and growth factors in brain metastasis formation. Invasion Metastasis 14:372-84, 1994. e-Pub 1994. PMID: 7657530.
- Nicolson GL, Nakajima M, Herrmann JL, Menter DG, Cavanaugh PG, Park JS, Marchetti D. Malignant melanoma metastasis to brain: role of degradative enzymes and responses to paracrine growth factors. J Neurooncol 18:139-49, 1994. e-Pub 1994. PMID: 7964976.
- Patton JT, Menter DG, Benson DM, Nicolson GL, McIntire LV. Computerized analysis of tumor cells flowing in a parallel plate chamber to determine their adhesion stabilization lag time. Cell Motil Cytoskeleton 26:88-98, 1993. e-Pub 1993. PMID: 8106174.
- Herrmann JL, Menter DG, Hamada J, Marchetti D, Nakajima M, Nicolson GL. Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol Biol Cell 4:1205-16, 1993. e-Pub 1993. PMID: 8305739.
- Marchetti D, Menter DG, Jin L, Nakajima M, Nicolson GL. Nerve growth factor effects on human melanoma cell invasion. Int J Cancer 55:692-699, 1993. e-Pub 1993.
- Menter DG, Patton JT, Updyke TV, Kerbel RS, Maamer M, McIntire LV, Nicolson GL. Transglutaminase stabilizes melanoma adhesion under laminar flow. Cell Biophys 18:123-43, 1991. e-Pub 1991. PMID: 1726525.
- Irimura T, McIsaac AM, Carlson DA, Yagita M, Grimm EA, Menter DG, Ota DM, Clary KR. Soluble factor in normal tissues that stimulates high-molecular-weight sialoglycoprotein production by human colon carcinoma cells. Cancer Res 50:3331-8, 1990. e-Pub 1990. PMID: 2334927.
- Crissman JD, Hatfield JS, Menter DG, Sloane BF, Honn KV. Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Res 48:4065-72, 1988. e-Pub 1988.
- Menter DG, Hatfield JS, Harkins C, Sloane BF, Taylor JD, Crissman JD, Honn KV. Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. Clin Exp Metastasis 5:65-78, 1987. e-Pub 1987. PMID: 3829498.
- Menter DG, Steinert BW, Sloane BF, Taylor JD, Honn KV. A new in vitro model for investigation of tumor cell-platelet-endothelial cell interactions and concomitant eicosanoid biosynthesis. Cancer Res 47:2425-32, 1987. e-Pub 1987. PMID: 3552214.
- Menter DG, Sloane BF, Steinert BW, Onoda J, Craig R, Harkins C, Taylor JD, Honn KV. Platelet enhancement of tumor cell adhesion to subendothelial matrix: role of platelet cytoskeleton and platelet membrane. J Natl Cancer Inst 79:1077-90, 1987. e-Pub 1987. PMID: 3479634.
- Menter DG, Harkins C, Onoda J, Riorden W, Sloane BF, Taylor JD, Honn KV. Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. Invasion Metastasis 7:109-28, 1987. e-Pub 1987. PMID: 3294727.
- Menter, DG, Gundlach, N, Steinert, BW, Diglio, C, Walz, D, Sloane, B F, Taylor, JD, Honn, KV. Platelet enhancement of tumor cell adhesion to endothelial cell extracellular matrix. Cancer Res 47:6751-62, 1987. e-Pub 1987.
- Menter DG, Honn KV, Onoda JM, Steinert BW, Diglio CA, Taylor JD, Crissman JD, Ryan RE, Sloane BF. Tumor cell-platelet-endothelial cell interactions and prostaglandin metabolism. Adv Prostaglandin Thromboxane Leukot Res 17B:981-85, 1987. e-Pub 1987.
- Menter DG, Harkins C, Onanda J, Craig R, Steinert B, Sloan B, Taylor D, Honn K. Platelet enhancement of tumor cell adhesion to subendothelial matrix: Role of platelet cytoskeleton and platelet membrane. J. Natl. Cancer Inst 79:1077-90, 1987. e-Pub 1987.
- Menter DG, Onoda JM, Moilanen D, Sloane BF, Taylor JD, Honn KV. Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation. J Natl Cancer Inst 78:961-9, 1987. e-Pub 1987. PMID: 3553692.
- Menter DG, Honn KV, Onoda JM, Caranaugh PG, Taylor JD, Crissman JD, Ryan RE, Sloane BF. Possible strategies for antimestatastic therapy. Prog Clin Biol 212:217-49, 1986. e-Pub 1986.
- Menter DG, Onoda JM, Taylor JD, Honn KV. Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Res 44:450-6, 1984. e-Pub 1984. PMID: 6362850.
- Menter DG, Honn KV, Onoda JM, Steinert BW, Diglio CA, Taylor JD, Sloane BF. Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis. Symp Fundam Cancer Res 36:361-88, 1983. e-Pub 1983. PMID: 6382514.
- Honn KV, Menter DG, Cavanaugh PG, Neagos G, Moilanen D, Taylor JD, Sloane BF. A review of prostaglandins and the treatment of tumor metastasis. Acta Clinica Belgica 38:53-67, 1983. e-Pub 1983.
- Menter DG, Obika M, Tchen TT, Taylor JD. Leucophores and iridiphors of Fundulus Heteroclitus: Biophysical and ultrastructural properties. J. of Morphology 160:103-120, 1979. e-Pub 1979.
- Obika M, Turner WA, Negeshi S, Menter DG, Lo SJ, Taylor JD, Tchen TT. The mechanisms of pigment migration in fish chromatophores. Pigment Cell 4:64-71, 1979. e-Pub 1979.
- Obika M, Menter DG, Tchen TT, Taylor JD. Actin microfilaments in melanophores of Fundulus heteroclitus. Cell Tissue Res 193:387-97, 1978. e-Pub 1978. PMID: 569547.
- Obika M, Turner WA, Negishi S, Menter DG, Tchen TT, Taylor JD. The effects of lumicolchicine, colchicine and vinblastine on pigment migration in fish chromatophores. J Exp Zool 205:95-110, 1978. e-Pub 1978. PMID: 670923.
- Kim S, Hashimoto Y, Cho S, Roszik J, Milton D, Dal F, Kim S, Menter D, Yang P, Ekmekcioglu S, Grimm E. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell and Melanoma. Pigment Cell and Melanoma.
Invited Articles
- Nicolson GL, Menter DG. Trophic factors and central nervous system metastasis. Cancer Metastasis Rev 14:303-21, 1996. e-Pub 1996.
- Menter DG, Herrmann JL, Nicolson GL. Neurotrophim: signals for invasion and survival. Cancer Bulletin 47:131-9, 1995. e-Pub 1995.
- Nicolson GL, Menter DG, Herrmann J, Cavanaugh P, Jia L, Hamada J, Yun Z, Nakajima M, Marchetti D. Tumor metastasis to brain: role of endothelial cells, neurotrophins, and paracrine growth factors. Crit Rev Oncog 5:451-71, 1994. e-Pub 1994. PMID: 8519808.
- Honn KV, Onoda JM, Menter DG, Taylor JD, Sloane BF. Arachidonic acid metabolism as a target for antimetastatic agents. The Cancer Bulletin 36:200-4, 1984. e-Pub 1984.
- Umar A, Steele V, Menter DG, Hawk E. Mechanisms of Non-steroidal Anti-inflammatory Drugs (NSAIDs) In Cancer Prevention. Seminars in Oncology.
Review Articles
- Menter DG, Bresalier RS. An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention. Annu Rev Pharmacol Toxicol 63:165-186, 2023. e-Pub 2022. PMID: 36202092.
- Menter DG, Afshar-Kharghan V, Shen JP, Martch SL, Maitra A, Kopetz S, Honn KV, Sood AK. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev 41(1):147-172, 2022. e-Pub 2022. PMID: 35022962.
- Kanikarla Marie, P, Fowlkes, NW, Afshar-Kharghan, V, Martch, SL, Sorokin, A, Shen, JY, Morris, VK, Dasari, NV, You, YN, Sood, AK, Overman, MJ, Kopetz, S, Menter, DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Frontiers in Oncology 11, 2021. e-Pub 2021. PMID: 34367949.
- Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep 21(2):5, 2019. e-Pub 2019. PMID: 30701321.
- Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33(6):965-983, 2018. e-Pub 2018. PMID: 29657130.
- Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG. Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. Front Oncol 8:107, 2018. e-Pub 2018. PMID: 29732316.
- Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev 36(2):199-213, 2017. e-Pub 2017. PMID: 28730545.
- Lam M, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG. The potential role of platelets in the consensus molecular subtypes of colorectal cancer. Cancer Metastasis Rev 36(2):273-288, 2017. e-Pub 2017. PMID: 28681242.
- Menter D. Preface. Cancer Metastasis Rev 36(2):193-194, 2017. e-Pub 2017. PMID: 28681239.
- Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev 36(2):235-248, 2017. e-Pub 2017. PMID: 28667367.
- Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol 28(3):468-477, 2017. e-Pub 2017. PMID: 27998963.
- Lee MS, Menter DG, Kopetz S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. J Natl Compr Canc Netw 15(3):411-419, 2017. e-Pub 2017. PMID: 28275039.
- Umar A, Steele VE, Menter DG, Hawk ET. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 43(1):65-77, 2016. e-Pub 2016. PMID: 26970125.
- Menter DG. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Drugs 11(12):1749-64, 2002. e-Pub 2002. PMID: 12457435.
- Nicolson GL, Menter DG, Herrmann JL, Yun Z, Cavanaugh P, Marchetti D. Brain metastasis: role of trophic, autocrine, and paracrine factors in tumor invasion and colonization of the central nervous system. Curr Top Microbiol Immunol 213 ( Pt 2):89-115, 1996. e-Pub 1996. PMID: 9053298.
- Menter DG, Herrmann JL, Nicolson GL. The role of trophic factors and autocrine/paracrine growth factors in brain metastasis. Clin Exp Metastasis 13:67-88, 1995. e-Pub 1995. PMID: 7882617.
- Nicolson GL, Menter DG. Trophic factors and central nervous system metastasis. Cancer Metastasis Rev 14:303-21, 1995. e-Pub 1995. PMID: 8821092.
Other Articles
- Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Tapia, C, Yang, F, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Wang, J, Westin, SN, Xi, Y, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F Author Correction. Nature communications 13(1), 2022. PMID: 34996889.
- Menter, DG Where is Waldo? or find the platelet. Cancer and Metastasis Reviews 40(3):649-655, 2021. PMID: 34591241.
Abstracts
- Hawk, ET, Menter, DG, Patterson, S, Swank, MW, DuBois A, RN. Linking Prostaglandin E2 Signaling, Lipid Rafts, and DNA Protein Kinase, 2012. e-Pub 2012.
- Menter DG, Yang P, Hsi L, Hoque A, Llansa ND, Mendosa G, Xi X, and Krishnan K. Differential effects of hydrophilic pravastatin and hydrophobic/lipophilic simvastatin on the growth of tumor cells from different organ sites. AACR Cancer Prevention Meeting, 2006. e-Pub 2006.
- Suraokar M, Kim J, Llansa N, Mendoza G, Logothetis CJ, Lippman SM, Menter DG. Tetracycline-inducible mouse U6 vector for conditional expression of shRNA. Proc Amer Assoc Cancer Res, 2005. e-Pub 2005.
- Kim J, Vakar-Lopez F, Thall P, Wang X, Stephens CL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Pereira P, Soto C, Menter DG, Lieberman R, McDonnell TJ, Lippman SM, Sabichi AL, Logothetis CJ, Troncoso P. The effects of selenium and vitamin E on apoptosis and proliferation in prostate tissue from a preprostatectomy study in patients with clinically organ-confined prostate cancer. Proc Amer Assoc Cancer Res, 2005. e-Pub 2005.
- Kim J, Yang P, Sabichi AL, Vakar-Lopez F, Llansa N, Mendoza G, Newman RA, Lippman SM, Menter DG. Peroxisome proliferator-activated receptor gamma activation by prostate stromal prostaglandin D2 synthase-derived eicosanoid products suppresses prostate cancer cell growth. . Proc. Amer. Assoc. Cancer. Res, 2004. e-Pub 2004.
- Kim K, Troncoso P, Thall PF, Wang X, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Johnson K, Taylor RJ, Menter DG, Lippman SM, Logothetis CJ, Lieberman R, Sabichi AL. Increased lipid peroxidation of lymphocytes in patients with prostate cancer treated with vitamin E or selenium preprostatectomy. Proc Amer Assoc Cancer Res, 2003. e-Pub 2003.
- Subbarayan V, Xu X, Llansa N, Mendoza G, Lippman SM, Menter DG. Arachidonic acid (AA) metabolizing enzyme, Fatty acid CoA Ligase 4 (FACL4) is up regulated in human prostate cancer. Proc Amer Assoc Cancer Res, 2003. e-Pub 2003.
- Salas TR, Jenster G, Kikuchi A, Chen S, Shemshedini L, Kim J, Logothetis CJ, Lippman SM, Menter DG. Glycogen synthase kinase-3b phosphorylates and suppresses the activity of the androgen receptor. Proc. Amer. Assoc. Cancer. Res, 2003. e-Pub 2003.
- Subbarayan V, Xu X, Llansa N, Lippman SM, Menter DG. Inverse relationship between the expression of PPARgamma and 15-Lox-2 in multiple tumor cell lines. Proc Amer Assoc Cancer Res, 2002. e-Pub 2002.
- Sabichi A, Subbarayan V, Llansa N, Lippman SM, Menter DG. Inverse Relationship Between the Expression of Peroxisome Proliferator Activated Receptor gamma and Cyclooxygenase-2 in Normal and Cancer Cells from the Human Prostate. Proc Amer Assoc Cancer Res, 2002. e-Pub 2002.
- Salas TR, Jenster G, Kikuchi A, Lippman SM, Menter DG. GSK-3b effects on the androgen receptor. Proc Amer Assoc Cancer Res, 2002. e-Pub 2002.
- Subbarayan V, Llansa N, Lippman SM, Menter DG. Prostate epithelial cells and prostate tumor cell lines express PPAR-g1 and -g2 isoforms. Proc. Amer. Assoc. Cancer. Res, 2001. e-Pub 2001.
- Menter DG, Sabichi AL, Lippman SM. Molecular effects of Selenium on prostate cells. Proc. Amer. Assoc. Cancer. Res, 2001. e-Pub 2001.
Book Chapters
- Menter DG, Lippman SM. Adjuvant approaches for preventing brain metastasis. In: Intracranial Metastasis: Current Management Strategies. Blackwell Publishing Inc, 445-60, 2004.
- Menter DG, Smith TW, Yun Z, PattonJ, McIntire LV, Nicolson GL. Adhesion stabilization of blood borne cancer cells in the microcirculation. In: Analytical use of Fluorescent Probes in Oncology. Plenum Press, 1996.
- Menter DG, Cavanaugh PG, Nicolson GL. Adhesion and growth properties of metastatic tumor cells that colonize specific organ sites. In: Metastasis: Adhesion and growth properties of metastatic tumor cells that colonize specific organ sites. S. Karger, 1996.
- Menter DG, Nicolson GL. Brain invasion, trophic factors, and central nervous system metastasis. In: Brain Tumor Invasion: Biological, Clinical and Therapeutic Considerations. John Wiley & Sons, 1996.
- Honn KV, Menter DG, Onoda JM, Steinert BW, Diglio CA, Taylor JD, Sloane BF. Tumor cell-platelet-endothelial cell interactions and prostaglandin metabolism. In: Advances in Prostaglandin Thromboxane and Leukotriene Research. Raven, 977-81, 1987.
- Honn KV, Menter DG, Steinert BW, Taylor JD, Onoda JM, Sloane BF. Analysis of platelet, tumor cell, and endothelial cell interactions and in vitro. In: Prostaglandins in Cancer Research. Springer-Verlag, 172-83, 1987.
- Steinert BW, Sloane BF, Menter DG, Taylor JD, Honn KV. Role of Eicosanoids in tumor cell-platelet-endothelial cell interactions. In: Anticarcinogenesis and radiation protein. Plenum Press, 63-70, 1987.
- Honn KV, Onoda JM, Menter DG, Cavanaugh PG, Taylor JD, Crissman D, Ryan RE, Sloane BF. Possible strategies for antimetastatic therapy. In: Cancer Metastasis: Experimental and Clinical Strategies. Alan R. Liss, 217-246, 1986.
- Honn KV, Onoda JM, Menter DG, Taylor JD, Sloane BF. Exogenous and endogenous prostacyclin, prostacyclin stimulating drugs synergistic with prostacyclin in the control of tumor metastasis. In: Biological Protection with Prostaglandins. CRC Press, 91-110, 1985.
- Honn KV, Menter DG, Onoda JM, Taylor JD, Sloane BF. Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis. In: Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. Raven Press, 361-388, 1984.
- Honn KV, Onoda JM, Menter DG, Taylor JD, Sloane BF. Prostacyclin-thromboxanes and tumor cell metastasis. In: Hemostatic mechanisms and metastasis. Martinus Nijhoff, 207-26, 1984.
- Honn KV, Menter DG, Moilanin D, Cavanaugh PG, Taylor JD, Sloane BF. Role of prostacyclin and thromboxanes in tumor cell-platelet-vessel wall interactions. In: Protective Agents in Cancer. Academic Press, 57-79, 1983.
- Menter DG, Dunn J, Palazzo R, Tchen TT, Taylor JD, Honn KV. Tumor cell induced platelet aggregation: inhibition by prostacyclin, thromboxane A2 and phosphodiesterase inhibitors. In: Prostaglandins and Cancer. Alan R. Liss, 809-813, 1982.
- Menter DG, Davis JS, Tucker SC, Hawk E, Crissman JD, Kopetz S, Honn KV. Platelets: "First Responders". In: Cancer Progression and Metastasis.
- Menter DG. The Evolution and Role of Platelets in Cancer Biology and Metastasis. In: Platelets in Disease: Thrombotic Disorders and Disorders not Involving Hemorrhage or Thrombosis. Springer Nature.
Patient Reviews
CV information above last modified July 22, 2026